Sionna Therapeutics completes Phase 1 dosing for NBD1 stabilizers SION-719 and SION-451, with Phase 2a trials set for 2025. Sionna Therapeutics announced the completion of Phase 1 dosing for its NBD1 ...
"Today's announcement brings us one step closer to our vision of developing novel NBD1-led proprietary dual combinations to transform the treatment paradigm for CF patients. The successful completion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results